Pediatric vasculitis

Current Rheumatology Reports

Volumn 14, Issue 2, 2012, Pages 121-129

  Batu, Ezgi Deniz ^a   Ozen, Seza ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

ANCA associated vasculitis; Beh et's syndrome; Child; Cutaneous polyarteritis nodosa; Henoch Sch nlein purpura; Kawasaki disease; Pediatric; Polyarteritis nodosa; Takayasu's arteritis; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; BEHCET DISEASE; CLINICAL FEATURE; CUTANEOUS POLYARTERITIS NODOSA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; LABORATORY TEST; LEUKOCYTOSIS; LOW DRUG DOSE; MOLECULAR EPIDEMIOLOGY; MORBIDITY; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PLASMAPHERESIS; POLYARTERITIS NODOSA; PROGNOSIS; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; SKIN BIOPSY; SYSTEMIC VASCULITIS; THROMBOCYTOSIS;

CHILD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PROGNOSIS; VASCULITIS;

EID: 84860835463     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0232-4     Document Type: Review

References (81)

1. Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr Rheumatol Rep. 2000;2:411-6.
2. Rowley AH, Ozen S, Sundel RP, et al. A clinician's pearls and myths in rheumatology. London: Springer; 2009. p. 219-29.
3. Ozen S. Problems in classifying vasculitis in children. Pediatr Nephrol. 2005;20:1214-8. (Pubitemid 41222964)
4. Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterization. Ann Rheum Dis. 2010;69:790-7.
5. •• Ozen S, Pistoiro A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798-806. This is the criteria validation for most of the vasculitides in childhood.
6. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PRES endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936-41.
7. Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children. Am J Dis Child. 1960;99:833-54.
8. Gedalia A. Henoch-Schönlein purpura. Curr Rheumatol Rep. 2004;6:195-202.
9. Saulsbury FT. Epidemiology of Henoch-Schönlein purpura. Cleve Clin J Med. 2002;69:SII87-9.
10. Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. 2007;22:2067-72. (Pubitemid 350090713)
11. Kawasaki Y, Suyama K, Yugeta E, et al. The incidence and severity of Henoch-Schönlein purpura nephritis over a 22-year period in Fukushima prefecture, Japan. Int Urol Nephrol. 2010;42:1023-9.
12. Kawasaki Y. The pathogenesis and treatment of pediatric Henoch- Schönlein purpura nephritis. Clin Exp Nephrol 2011, In press.
13. Shin JI, Song KS, Kim H, et al. The gene expression profile of matrix metalloproteinases and their inhibitors in children with Henoch-Schönlein purpura. Br Assoc Dermatol. 2011;164:1348-55.
14. Chen T, Guo Z-P, Li M-M, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schönlein purpura. Clinical and Experimental Immunology 2011, In press.
15. Brogan P, Bagga A. Leukocytoclastic vasculitis. In: Cassidy JT, Petty RE, Laxer RM, et al., editors. Textbook of pediatric rheumatology. Philadelphia: Saunders Elsevier; 2011. p. 482-97.
16. Roberts PF, Waller TA, Brinker TM, et al. Henoch-Schönlein purpura: a review article. South Med J. 2007;100(8):821-4.
17. Chen S-Y, Kong M-S. Gastrointestinal manifestations and complications of Henoch-Schönlein purpura. Chang Gung Med. 2004;27:175-81. (Pubitemid 38568729)
18. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90:916-20. (Pubitemid 41232341)
19. Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet. 2007;369(9566):976-8.
20. Rostoker G. Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001;15 (2):99-138.
21. Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol. 2002;16(3):411-25.
22. •• Davin J-C. Henoch-Schönlein purpura nephritis: pathophysiology, treatment and future strategy. Clin J Am Soc Nephrol. 2011;6:679-89. This is an excellent review describing the treatment strategies on pathogenetic pathways in HSP.
23. Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch- Schönlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol. 1998;49(1):9-14. (Pubitemid 28043360)
24. Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch- Schönlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001;21:128-33. (Pubitemid 32453691)
25. Goldstein AR, White RHR, Akuse R, et al. Long term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992;339:280-2.
26. Wakaki H, Ishikura K, Hataya H, et al. Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol. 2011;26:921-5.
27. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr. 2004;163:285-91. (Pubitemid 38725531)
28. De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301-8. (Pubitemid 350200347)
29. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708-33. (Pubitemid 41754943)
30. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533-44. (Pubitemid 39070416)
31. Yanagawa H, Nakamura Y, Kawasaki T, et al. Nationwide epidemics of Kawasaki disease in Japan during winter of 1985-86. Lancet. 1986;2(8516):1138-9. (Pubitemid 17174481)
32. Burgner D, Davilla S, Breunis WB, et al. International Kawasaki Disease Genetic Consortium: a genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PloS Genet. 2009;5(1):e1000319.
33. Oh JH, Han JW, Lee SJ, et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr Cardiol. 2008;29:402-8.
34. Hsieh Y-Y, Lin Y-J, Chang C-C, et al. Human lymphocyte antigen B-associated transcripts 2,3 and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm. J Clin Lab Anal. 2010;24:262-8.
35. Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr. 2009;168:157-62.
36. Levy M, Karen G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J. 1990;9:122-6. (Pubitemid 20084949)
37. Pinna GS, Kafetzis DA, Tselkas OI, et al. Kawasaki disease: an overview. Curr Opin Infect Dis. 2008;21:263-70. (Pubitemid 351620381)
38. Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010;9:441-8.
39. •• Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol. 2011;In press. This is the most recent review defining clearly the challenges in KD
40. Tse SM, Silverman ED, Mc Crindle BW, et al. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr. 2002;140:450-5. (Pubitemid 34494318)
41. Sugahara Y, Ishii M, Muta H, et al. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol. 2008;29:398-401.
42. Furukawa T, Kishiro M, Akimoto M, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93:142-6. (Pubitemid 351204755)
43. McCrindle BW. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. 2009;120:6-8.
44. Ozen S, Bakkaloglu A, Dusunsel R, et al. Childhood vasculitis in Turkey: a nationwide survey. Clin Rheumatol. 2007;26:196-200. (Pubitemid 46020243)
45. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145:517-22. (Pubitemid 39345990)
46. Ozen S, Ben-Chetrit E, Bakkaloglu A, et al. Polyarteritis nodosa associated with familial mediterranean fever: is it an association? Semin Arthritis Rheu. 2001;30:281-7. (Pubitemid 32172733)
47. Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr. 2007;166:145-51. (Pubitemid 46025506)
48. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203-11.
49. Dillon MJ, Eleftherious D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol. 2010;25:1641-52.
50. Dillon MJ. Vasculitis treatment: new therapeutic approaches. Eur J Pediatr. 2006;165:351-7.
51. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44. (Pubitemid 36765101)
52. Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int. 2011;In press.
53. Fathalla BM, Miller L, Brady S, et al. Cutaneous polyarteritis nodosa in children. J Am Acad Dermatol. 2005;53:724-8. (Pubitemid 41399955)
54. David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child. 1993;69:685-8. (Pubitemid 24009916)
55. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005;38:93-103. (Pubitemid 40515009)
56. Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360 (9341):1197-202. (Pubitemid 35232718)
57. Vamvakopoulos J, Savage CO, Harper L. ANCA-associated vasculitides- lessons from the adult literature. Pediatr Nephrol. 2010;25:1397-407.
58. Zwerina J, Eger G, Englbrecht M, et al. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patient. Semin Arthritis Rheum. 2008;39:108-15.
59. Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis & Rheumatism. 2007;52(5):837-44. (Pubitemid 46932091)
60. Vanoni F, Bettinelli A, Keller F, et al. Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol. 2010;25:205-12.
61. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919-29. (Pubitemid 24179154)
62. Sharma BK, Sagar S, Chugh KS, et al. Spectrum of renovascular hypertension in the young in north India. Angiology. 1985;36:370-8.
63. Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270-5.
64. Vanoli M, Daina E, Salvarini C, et al. Takayasu arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005;53:100-7. (Pubitemid 40216358)
65. Hahn D, Thomson PD, Kala U, et al. A review of Takayasu's arteritis in children in Gauteng, South Africa. Pediatr Nephrology. 1998;12:668-75. (Pubitemid 28472926)
66. •• Morishita KA, Rosendahl K, Brogan P. Familial Takayasu arteritis -a pediatric case and a review of the literature. Pediatr Rheum. 2011;In press. This is a recent review of familial TA cases in the literature encouraging the search for candidate genes in TA pathogenesis.
67. Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35:913-9. (Pubitemid 351747137)
68. Yamada I, Nakagawa T, Himero Y, et al. Takayasu arteritis: diagnosis with breath hold contrast enhanced 3-dimensional MR angiography. J Magn Reson Imaging. 2000;II:481-7.
69. Koening CL, Langford CA. Novel therapeutic strategies for large vessel vasculitis. Rheum Dis Clin North Am. 2006;32:173-86. (Pubitemid 43290598)
70. Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150:72-6. (Pubitemid 44940894)
71. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;12:16-24. (Pubitemid 40075643)
72. Lee GY, Jang SY, Ko SM, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol. 2011;In press.
73. Ozen S. The 'other' vasculitic syndromes and kidney involvement. Pediatr Nephrol. 2010;25(9):1633-9.
74. Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58:3951-9.
75. Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum. 2009;61:600-4.
76. •• Ozen S. Pediatric onset Behçet disease. Curr Opin Rheumatol. 2010;22:585-89. This is a recent review of childhood Behçet's syndrome.
77. • Fei Y, Webb R, Cobb BL, et al. Identification of novel genetic susceptibility loci for Behçet's disease using a genome-wide association study. Arthritis Res Ther. 2009;11:R66. This was the first GWAS in Behçet's syndrome.
78. Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet. 2010;42(8):703-6.
79. International Study Group for Behcet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078-80.
80. Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee, EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-62.
81. Cantarini L, Tinazzi I, Caramaschi P, et al. Safety and efficacy of etanercept in children with juvenile-onset Behcet's disease. Int J Immunopathol Pharmacol. 2009;22:551-5.